Investigational Drug Information for AG-120
✉ Email this page to a colleague
What is the development status for investigational drug AG-120?
AG-120 is an investigational drug.
There have been 28 clinical trials for AG-120.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2019.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Cancer Institute (NCI), and Institut de Recherches Internationales Servier.
There are twenty US patents protecting this investigational drug and two hundred and ninety-eight international patents.
Summary for AG-120
| US Patents | 20 |
| International Patents | 298 |
| US Patent Applications | 118 |
| WIPO Patent Applications | 110 |
| Japanese Patent Applications | 20 |
| Clinical Trial Progress | Phase 3 (2019-03-01) |
| Vendors | 41 |
Recent Clinical Trials for AG-120
| Title | Sponsor | Phase |
|---|---|---|
| Ivosidenib or Enasidenib Followed by Azacitidine Plus Venetoclax or Azacitidine Plus Venetoclax Followed by Ivosidenib or Enasidenib for the Treatment of IDH Mutated Acute Myeloid Leukemia in Older Patients. The I-DATA Study | Alice Mims | Phase 2 |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | National Cancer Institute (NCI) | Phase 1 |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | M.D. Anderson Cancer Center | Phase 1 |
Clinical Trial Summary for AG-120
Top disease conditions for AG-120
Top clinical trial sponsors for AG-120
US Patents for AG-120
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AG-120 | ⤷ Subscribe | Methods of treatment of malignancies | Celgene Corporation (Summit, NJ) Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Subscribe |
| AG-120 | ⤷ Subscribe | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Subscribe |
| AG-120 | ⤷ Subscribe | Methods of treatment of malignancies | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Subscribe |
| AG-120 | ⤷ Subscribe | Pharmaceutical compositions of therapeutically active compounds | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Subscribe |
| AG-120 | ⤷ Subscribe | Methods and compositions for cell-proliferation-related disorders | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Subscribe |
| AG-120 | ⤷ Subscribe | Therapeutically active compositions and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Subscribe |
| AG-120 | ⤷ Subscribe | Combination therapy for treating malignancies | Agios Pharmaceuticals, Inc. (Cambridge, MA) Celgene Corporation (Summit, NJ) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AG-120
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AG-120 | Australia | AU2016393869 | 2036-02-26 | ⤷ Subscribe |
| AG-120 | Australia | AU2016393870 | 2036-02-26 | ⤷ Subscribe |
| AG-120 | Canada | CA3015753 | 2036-02-26 | ⤷ Subscribe |
| AG-120 | Canada | CA3015757 | 2036-02-26 | ⤷ Subscribe |
| AG-120 | China | CN109069410 | 2036-02-26 | ⤷ Subscribe |
| AG-120 | European Patent Office | EP3419593 | 2036-02-26 | ⤷ Subscribe |
| AG-120 | European Patent Office | EP3419594 | 2036-02-26 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
